公开(公告)号：KR101745278B1

公开(公告)日：2017-06-08

申请号：KR1020160121335

申请日：2016-09-22

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  김상두

IPC: A61K38/08 ,  A61K31/19 ,  C07K7/06

Abstract: 본발명은서열번호 1의아미노산서열로이루어진펩타이드를유효성분으로포함하는류마티스관절염예방또는치료용약학적조성물에관한것이다. 본발명에따른약학적조성물은류마티스관절염병인과정에서중요한 Th17 세포및 T세포분화및 활성화저해와더불어, 파골세포의생성및 활성화를저해하는효과를가지는바, 류마티스관절염의근본적인치료에적용될수 있을것으로기대된다.

Abstract translation: 本发明涉及包含由SEQ ID NO：2的氨基酸序列组成的肽的预防或治疗类风湿性关节炎的物质的药物组合物：1，作为活性成分。 根据本发明的药物组合物是，它可以被施加到杆的基本治疗，类风湿性关节炎具有这样的效果，具有重要的Th17细胞和T细胞的分化和类风湿关节炎的发病机制过程激活的抑制，抑制破骨细胞生成和激活 预计。

公开(公告)号：KR101303991B1

公开(公告)日：2013-09-04

申请号：KR1020110024239

申请日：2011-03-18

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  김상두

IPC: A61K31/18 ,  A61P29/00 ,  A61P31/04

CPC classification number: A61K31/18 ,  A23L33/10 ,  A23V2002/00 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2059 ,  A61K9/4866 ,  A61K31/192 ,  A61K47/20 ,  A23V2200/324

Abstract: 본 발명의 목적은
m -3M3FBS 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 조성물을 제공함에 있다. 또한 본 발명의 또다른 목적은
m -3M3FBS을 포함하는 염증성 질환 또는 감염성 질환의 개선 또는 예방용 건강기능식품을 제공함에 있다.
본 발명의
m -3M3FBS는 살균효과, 세포사멸억제, LPS관여 신호전달을 억제하는 효과를 나타내는 바, 염증성 질환 또는 감염성 질환의 효과적인 치료 또는 예방을 가능하게 하므로 염증성 질환 또는 감염성 질환의 치료 또는 예방을 위한 의약품 또는 건강기능식품으로 유용하게 사용될 수 있다.

公开(公告)号：KR1020140148325A

公开(公告)日：2014-12-31

申请号：KR1020140074491

申请日：2014-06-18

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  김상두

IPC: A61K38/08 ,  A61P19/02 ,  A61P19/00

CPC classification number: A61K38/08 ,  A61K31/19 ,  C07K7/06

Abstract: The present invention relates to a pharmaceutical composition containing peptides consisting of amino acid sequences of SEQ ID: 1 for preventing or treating rheumatoid arthritis. According to the present invention, the pharmaceutical composition has an effect of inhibiting cell differentiation and activation of Th17 and TFH, important in a process of rheumatoid arthritis occurrence, and an effect of inhibiting generation and activation of osteoclasts. Therefore, the pharmaceutical composition is expected to be applied to fundamentally treat rheumatoid arthritis.

Abstract translation: 本发明涉及包含由SEQ ID：1的氨基酸序列组成的用于预防或治疗类风湿性关节炎的药物组合物。 根据本发明，药物组合物具有抑制Th17和TFH的细胞分化和活化的作用，在类风湿性关节炎发生过程中是重要的，以及抑制破骨细胞产生和活化的作用。 因此，药物组合物预期用于从根本上治疗类风湿性关节炎。

公开(公告)号：KR1020140024686A

公开(公告)日：2014-03-03

申请号：KR1020120090978

申请日：2012-08-20

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  김상두

IPC: A61K38/08 ,  A61P1/04 ,  A61P1/00

CPC classification number: A61K38/08 ,  A23L33/18 ,  C07K7/06

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease which includes peptide comprising amino acid sequence of WKYMVm or pharmaceutically acceptable salts thereof, to health supplement for preventing or reducing the inflammatory bowel disease which includes the peptide or cytologically acceptable salts thereof as an active ingredient, and to a method for preventing or treating animals except humans which includes a step which administers the pharmaceutically acceptable composition into entities which require the same. The peptide WKYMVm recovers colic shortage, weight decrease, bleeding index increase or defecation index increase which are symptoms of the inflammatory bowel disease so that the peptide WKYMVm can be used for the pharmaceutical composition for preventing or treating the inflammatory bowel disease and for the health supplement. [Reference numerals] (AA,BB) Normal

Abstract translation: 本发明涉及一种预防或治疗炎症性肠病的药物组合物，其包括含有WKYMVm的氨基酸序列的肽或其药学上可接受的盐，用于预防或减少炎症性肠病的健康补充剂，其包括肽或其细胞学上可接受的盐 作为活性成分，以及用于预防或治疗除人以外的动物的方法，其包括将药学上可接受的组合物施用于需要其的实体的步骤。 肽WKYMVm恢复肠炎不足，体重减轻，出血指数增加或排便指数增加，这是炎性肠病的症状，使得肽WKYMVm可用于预防或治疗炎症性肠病和健康补充剂的药物组合物 。 （标号）（AA，BB）正常

公开(公告)号：KR1020120041875A

公开(公告)日：2012-05-03

申请号：KR1020100103259

申请日：2010-10-22

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  김상두

IPC: A61K38/06 ,  A61P29/00 ,  A61P31/00

CPC classification number: C07K5/0823 ,  A61K38/06

Abstract: PURPOSE: A composition containing a peptide ligand is provided to promote bacteria removal and to suppress inflammation. CONSTITUTION: A pharmaceutical composition for treating inflammatory and infectious diseases contains a peptide ligand which binds to CXCR2 as an active ingredient. The peptide ligand is Ac-PGP(acetylated-Pro-Gly-Pro). The composition additionally contains a pharmaceutically acceptable carrier, excipient, or diluents. The composition is formulation for subcutaneous injection.

Abstract translation: 目的：提供含有肽配体的组合物以促进细菌去除并抑制炎症。 构成：用于治疗炎性和感染性疾病的药物组合物含有与CXCR2结合的肽配体作为活性成分。 肽配体是Ac-PGP（乙酰化-Pro-Gly-Pro）。 该组合物另外含有药学上可接受的载体，赋形剂或稀释剂。 组合物是用于皮下注射的制剂。